Effect of Exercise, Endocannabinoids and Ketones on Cerebral Metabolism in a Cognitive Disorders Population

NCT ID: NCT04322461

Last Updated: 2025-06-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

14 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-01

Study Completion Date

2024-05-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A two months intervention in which two groups of cognitive disorders, Parkinson and Alzheimer's disease, will receive 50g/day of a commercial MCT supplement combined with supervised aerobic exercise 3 times/week. Cognition and ketones will be assess before and after the intervention, along with endocannabinoids plasma concentrations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson disease

2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.

Group Type EXPERIMENTAL

Betaquik MCT supplement

Intervention Type DIETARY_SUPPLEMENT

50g/day divided in 3. Breakfast, lunch and dinner

Alzheimer's disease

2 months intervention with 50g/day of a commercial MCT supplement combine with supervised aerobic exercise 3x/week.

Group Type EXPERIMENTAL

Betaquik MCT supplement

Intervention Type DIETARY_SUPPLEMENT

50g/day divided in 3. Breakfast, lunch and dinner

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Betaquik MCT supplement

50g/day divided in 3. Breakfast, lunch and dinner

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Alzheimer's or parkinson disease diagnostic
* Stable medication associated with the disease
* Able to consent
* Presence of an accompanying person for the first and last visit.
* Ability to read and talk in French

Exclusion Criteria

* MMSE \< 20
* MCT or coconut oil supplementation
* Coconut allergy
* Cannabis, THC or CBD consumption
* Excessive alcohol consumption
* Physical activity 3x/week
* Presence of an metallic object in the body
* Impossibility to lay in dorsal decubitus for 40 minutes
* Cardiac disease
* Any uncontrolled disease that could interfer with the project.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Société des Produits Nestlé (SPN)

INDUSTRY

Sponsor Role collaborator

Université de Sherbrooke

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stephen Cunnane, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Université de Sherbrooke

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre de recherche sur le vieillissement

Sherbrooke, Quebec, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-3436

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.